Shots:
- Boston Scientific has agreed to acquire Bolt Medical, strengthening its cardiovascular portfolio with the addition of Bolt IVL system for coronary & peripheral disease. Deal is expected to close in H1’25
- Boston, an investor with a 26% equity stake in Bolt Medical, is acquiring the rest 74% for $443M upfront & up to $221M regulatory milestones. (Deal is valued at $600M upfront & up to $300M milestones if the acquisition was for 100% stake)
- The Bolt IVL System uses lithotripsy to remove calcium in calcified lesions. The pivotal (RESTORE ATK & BTK) studies of Bolt IVL ATK & BTK Systems for PAD are completed, with data supporting the FDA’s approval & CE mark; another global FRACTURE IDE trial of Bolt IVL Coronary System for CAD has begun in Dec 2024
Ref: Boston Scientific | Image: Bolt Medical
Related News:- Boston Scientific Reports the Acquisition of Silk Road Medical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
